Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
24 avr. 2024 07h59 HE
|
Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27 mars 2024 08h30 HE
|
Allarity Therapeutics, Inc.
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
06 mars 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
22 févr. 2024 06h05 HE
|
RetinalGeniX Technologies, Inc.
RetinalGeniX Granted A New Patent for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
26 déc. 2023 12h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
21 déc. 2023 05h50 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD
Wistar Scientists Identify Esophageal Cancer Biomarkers
06 déc. 2023 10h09 HE
|
The Wistar Institute
Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology. Under the...
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
05 déc. 2023 07h30 HE
|
Allarity Therapeutics, Inc.
All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization...
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
04 déc. 2023 14h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS
DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
01 déc. 2023 12h32 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO
Virender Ahluwalia will serve as Interim Chief Financial Officer